Streetbeat News

AUPH

Aurinia Pharmaceuticals Inc.

https://www.auriniapharma.com

Industry

Biotechnology

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Aurinia Pharmaceuticals reported Q1 2024 earnings with a GAAP EPS of $(0.07), surpassing the $(0.14) estimate. Sales reached $50.3M, exceeding the $47.453M forecast, marking a 46.18% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 10:01 am

Aurinia Pharmaceuticals has launched initiatives to enhance awareness about Lupus Nephritis, emphasizing the importance of regular screening and effective management.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 10:19 am

The FDA has approved an updated label for LUPKYNIS (voclosporin), removing the previous one-year limitation and now including three-year data from the AURORA 2 study. This study showcased the long-term safety and efficacy of LUPKYNIS in treating lupus nephritis in combination with other treatments.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 10:13 am

HC Wainwright & Co. analyst Ed Arce reiterates a Buy rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) with a maintained price target of $13.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 7:09 pm

Aurinia Pharmaceuticals Inc. has been granted exemptive relief by Canadian securities regulators, allowing the company to proceed with its share repurchase program. This decision enables Aurinia to buy back shares under certain conditions, potentially impacting its stock price positively in the short term due to the reduced supply of shares and increased investor confidence.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 2:10 pm

Cantor Fitzgerald analyst Olivia Brayer maintains an Overweight rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) but lowers the price target from $12 to $10.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 5:11 pm

Top Wall Street analysts have updated their price targets and ratings for several US-listed companies, including raising and lowering price targets for stocks like Wix.com Ltd. (WIX), Analog Devices, Inc. (ADI), and others. These changes reflect analysts' latest views on these companies, potentially influencing their stock prices in the short term.

Portfolio Pulse from Avi Kapoor

February 22, 2024 | 12:23 pm

HC Wainwright & Co. analyst Ed Arce maintains a Buy rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) but lowers the price target from $15 to $13.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 11:44 am

RBC Capital analyst Douglas Miehm has maintained an Outperform rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) but lowered the price target from $13 to $8.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 4:13 pm

Herbalife Ltd. (NYSE:HLF) shares plummeted by approximately 36% due to disappointing quarterly earnings, missing market expectations. The article also highlights significant movements in other stocks during Thursday's mid-day session, including notable gainers like JX Luxventure Limited and losers such as Treasure Global Inc.

Portfolio Pulse from Avi Kapoor

February 15, 2024 | 6:20 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.